Used in the treatment of chronic myeloid leukemia (CML), particularly in patients who are resistant or intolerant to prior therapy including imatinib. It functions as a selective Bcr-Abl tyrosine kinase inhibitor, effectively targeting the abnormal protein responsible for the uncontrolled growth of leukemic cells. Its ability to maintain potency against several imatinib-resistant mutations makes it valuable in second-line therapy. It is taken orally and designed to achieve sustained inhibition of Bcr-Abl signaling, helping to induce and maintain hematologic and cytogenetic responses in affected patients.